Karyopharm Therapeutics is a Massachusetts-based pharmaceutical company that develops drugs. Its filings show it lobbied Congress about rare disease policy and the drug approval process, likely to influence rules for how medicines for rare conditions are reviewed and approved. It reported about $100,000 in lobbying across three filings and used the law firm Sidley Austin.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
ABIGAIL CARROLL
The latest disclosures for this client.
SIDLEY AUSTIN LLP
Q3YSIDLEY AUSTIN LLP
Q2The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
SIDLEY AUSTIN LLP
ms PATTIE LOUISE DELOATCHE
SIDLEY AUSTIN LLP
SIDLEY AUSTIN LLP
Q1SIDLEY AUSTIN LLP
Q4SIDLEY AUSTIN LLP
RASIDLEY AUSTIN LLP
RR